Paying for pharmaceutical registration in developing countries

Health Policy and Planning

Volumn 18, Issue 3, 2003, Pages 237-248

  Kaplan, Warren A ^a   Laing, Richard ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Developing country; Drug policy; Pharmaceutical regulation; Registration fees

Indexed keywords

GENERIC DRUG;

ARTICLE; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC DEVELOPMENT; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; REGISTRATION;

DEVELOPING COUNTRIES; DRUG APPROVAL; DRUG INDUSTRY; DRUGS, GENERIC; DRUGS, INVESTIGATIONAL; FEES AND CHARGES; HEALTH EXPENDITURES; HUMANS;

EID: 0042236953     PISSN: 02681080     EISSN: None     Source Type: Journal    
DOI: 10.1093/heapol/czg030     Document Type: Article

References (28)

1. Abraham J. 2002. Making regulation responsive to commercial interests: streamlining drug industry watchdogs. British Medical Journal 325: 1164-7.
2. Alliance of Manufacturers and Exporters. 1999. Registration fees: where does the buck stop? A study of federal cost recovery. Available at http://www.the-alliance.org, accessed August 12, 2002.
3. CMR International. 2001. R&D Briefing No. 31: Profile of performance (3) Review times. At http://www.cmr.org/pdfs/rd31.pdf, accessed December 3, 2002.
4. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10: 107-42.
5. European Federation of Pharmaceutical Industries and Associations. 1999. The pharmaceutical industry in figures. 1999 Edition, page 3. At http://www.efpia.org/6_publ/document/ pharma99.pdf, accessed September 34, 2002.
6. Food and Drug Administration. 2002. Prescription Drug User Fee Act (PDUFA). Available at http://www.fda.gov/oc/pdufa/ default.htm, accessed August 1, 2002.
7. Government Accounting Office. 2002. Food and Drug Administration: effect of user fees on drug approval times, withdrawals, and other agency activities. GAO-02-958. Washington DC.
8. IMS Data Group. 2002. World Pharma Sales 2001: U.S. still driving growth. Available at http://www.ims-global.com, accessed August 17, 2002.
9. IMS-Health. 2002. At http://www.imshealth.com, accessed September 2, 2002.
10. Jayasuriya DC. 1985. Regulation of pharmaceuticals in developing countries: legal issues and approaches. ISBN 924 156089 4. Geneva: World Health Organization.
11. Jayasuriya DC. 2002. Medicinal products and the law in developing countries - concepts, issues and approaches. New Delhi: Har-Anand Publications Pvt, Ltd.
12. LABAT AFRICA/Chemical Marketing and Consulting Services. 2002. Pharmaceutical manufacturing sector study, South Africa. July 2002, p. 26. Copy available from authors.
13. Management Sciences for Health. 1997. Managing drug supply. 2nd edition. West Hartford, CT: Kumarian Press.
14. Office of Technology Assessment, U.S. Congress. 1993. Pharmaceutical R&D: costs, risks and rewards. Washington, DC: U.S. Government Printing Office.
15. Ratanawijitrasin S, Wondemagegnehu E. 2002. Effective drug regulation: a multicountry study. 1st edition, ISBN 92 4 156206 4. Geneva: World Health Organization.
16. Sachs J et al. 2001. Macroeconomics and Health: Investing in health for economic development. ISBN 924 154550 X. Geneva: World Health Organization, Commission on Macroeconomics and Health.
17. Taylor RB, Shakoor O, Behrens RH. 1995. Drug quality, a contributor to drug resistance? The Lancet 346: 122.
18. Thompson L. 2000. Registration fees for faster drug reviews: are they helping or hurting the public health? FDA Consumer Magazine, September-October, available at http://www.fda. gov/fdac/features/2000/500_pdufa.html, accessed August 2, 2002.
19. United States Department of Commerce, Commercial Service, at http://www.usatrade.gov, accessed September 12, 2002.
20. Weerasuriya K. 1993. Essential drugs and registration of pharmaceuticals: the Sri Lankan experience. Bulletin of the World Health Organization 71: 229-35.
21. Weerasuriya K. 1999. Registration of new drugs in developing countries. The Lancet 353: 2161-2.
22. Wendo C. 2001. Uganda's drug regulatory agency faces financial crisis. The Lancet 358: 482.
23. WHO. 1999a. Effective drug regulation: what can countries do? Technical Report Series, WHO/HTP/EDM/MAC (11)/99.6. Geneva: World Health Organization.
24. WHO. 1999b. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products. WHO/DMP/RGS98.5. Geneva: World Health Organization.
25. WHO. 1999c. Pharmaceuticals in the Americas. WHO/HTP/EDM/99.1, Geneva: World Health Organization.
26. WHO. 2000. World Health Report 2000, Health systems: improving performance. Geneva: World Health Organization.
27. WTO. 2001. Declaration on the TRIPS Agreement and Public Health (14 November 2001). World Trade Organization, at http://www.wto-org/english/thewto_e/minist_e/min01_e/minde cl_trips_e.htm, accessed October 8, 2002.
28. Young B, Surrusco M. 2001. Rx R&D Myths: the case against the drug industry's R&D "Scare Card". Washington, DC: Public Citizen.